International Journal Dental and Medical Sciences Research
Volume 4, Issue 5, Sep-Oct 2022 pp 137-143 www.ijdmsrjournal.com ISSN: 2582-6018

Nasopharyngeal Non-Hodgkin's Lymphoma – a Case Report and Review of Literature

Dr. Maheshwari Vengat*, Dr. Jabin Thankachan Paul,Dr. Ligil Aksa George,Dr. Binil Benny, Dr. Albin Regi

[1] *Pharm D, MSc Oncology, University of Chester, England, United Kingdom*
[2,3,4,5] *Doctor of pharmacy, Department of pharmacy practice, Teerthanker Mahaveer college of pharmacy, TMU, Moradabad, 24001, UttarPradesh,India*

Submitted: 07-09-2022 Accepted: 17-09-2022

ABSTRACT: Lymphomas are immune system solid tumors that account for 15% of all head and neck cancers. NHLs (non-Hodgkin lymphomas) are a cluster of lymphoproliferative illnesses caused by B-, T-, or natural killer Cells. They exhibit a broad series of histological and diagnostic structures at the moment of manifestation, rendering diagnosis testing. A fifty-eight-year-old man accessible with a one-month past of edema in the higher right rear tooth location following extraction. The excised socket had minor nodular lesion growth on intraoral inspection. Histological analysis of the biopsy samples exposed pieces of small rotund cells with hyperchromatic nuclei, similar to lymphoblast. T-cell NHL is confirmed by immunohistochemistry (IHC). The determination of this case study is to inspect the clinical exhibition as well as histological significance of minor rotund cell tumors of the jaw, as well as the discrepancy analysis of minor rotund cell tumors.

KEYWORDS: Immunohistochemistry,non-Hodgkin lymphoma, T-cell lymphoma

I. INTRODUCTION

Lymphomas are a diverse cluster of cancers that arise from lymphocytes. Improved diagnostic, pathological, and genetic data have aided in the categorization of lymphomas in recent times, as evidenced by the World Health Organization's (WHO) categorization modification in 2016. This detects more than forty mature B-cell neoplasms, as well as more than 26developed T-cell and natural killer (NK)-cell neoplasms. Entire lymphomas, excluding Hodgkin's lymphoma (HL), are classified as non-Hodgkin lymphoma (NHL).[22]. There have been continuous indications of a rise in the number of NHL globally over the last three decades. Men have an occurrence that is almost two times that of women. While specific subtypes of NHL, such as Burkitt lymphoma as well as lymphoblastic lymphoma, have been identified at anearlierstage, the typical age of analysis is about the sixth decade of lifetime.

Lymphomas appear as swollen, non-tender lymph nodes, but they can also affect extranodal areas, such as the digestive system and the skull and neckline. In HL, extra nodal participation is far less frequent than in NHL.

New advancements in molecular genetics have aided the considerate of the genetics of these disorders greatly. The use of gene countenance levels has resulted in the identification of new cancerous signaling lanes in the malignant procedure of alteration. [24]. These studies have also discovered new molecular lymphoma subtypes that are histopathologic ally identical. The current treatment of proliferatingmidpoint B cell similar distributed massive Bcell lymphoma (DLBCL) as well as activating B cell comparable DLBCL differs significantly, with major differences in overall survival after primary therapy.

II. PATIENT INFORMATION

A fifty-eight-year-old male patient came to the hospital with a one-month history of bulge and soreness in the gums around his right upper back tooth. The lesion began as a tiny bulge and grew until it reached its current size.[12] A month ago, my medical history revealed epistaxis as well as blood on coughing for a month. The patient also revealed that he had removal in that area two months prior after noticing a weakening of his teeth, which went smoothly. Family history has no bearing on the outcome. Extraoral investigation demonstrates modest edema in the right side's center third of the face.

International Journal Dental and Medical Sciences Research
Volume 4, Issue 5, Sep-Oct 2022 pp 137-143 www.ijdmsrjournal.com ISSN: 2582-6018



Figure 1: (a) Orthopantomograph, (b) PNS view
Source: Singaraju et al., (2020)

III. CLINICAL FINDINGS

[8] Intraoperatively, a single massive nodular proliferative development stretching from the right second premolar area to the maxillary tuberosity region, as well as up to the mid-palate area without passing the midline, was understood on the right maxillary edge. On examination, it felt tender. Beneath 14, there was a soft-tissue tumor projecting from the removalopening. The mucosa above it was a reddish-pink color. The bulge was sessile, with imprecise boundaries, a reddish-pink tint, and a hard substance. The lymph nodes in the area were not palpable.

Non-Hodgkin lymphomas (NHL) are a diverse category of lymphoproliferative cancers that are significantly less predictable than Hodgkin's lymphomas and have a much higher proclivity for spreading to extranodal sites. Nearly a quarter of NHL cases occur in non-nodal locales, with the majority of these involving both nodal and extranodal sites.

IV. TIMELINE

The patient has a one-month history of bulge and soreness in the gums around his right upper back. Under general anesthesia, the lesion was surgically removed, and postoperative radiation and chemotherapy were scheduled. A two-year continuation found no local occurrence.

V. DIAGNOSTIC TESTS

A tentative diagnosis of nasopharyngeal cancer of the maxillary antrum was made constructed on the patient's history and medical features, with carcinoma of the maxillary antrum as a diagnostic process.

Several radiographic and regular hematological tests were out. Orthopantomography and a paranasal sinus image were used in the radiological study. On the right side of the orthopantomography, there was the erosion of maxillary antral bone with unkempt margins. The right orbit's floor shows signs of bone loss. There was a soft-tissue shadowing across the alveolar ridge on the correct side, with complete loss of the alveolar bone. [13] The coronoid as well as condylar lobes showed adequate growth. The upper, medial, and anterior sidewalls of the middle maxillary antrum, as well as the development of the malar bone on the right side alongside and the middle and inferior nasal conchae medial and lateral, were all obliterated. [23]. Furthermore, the middle infraorbital boundary was killed due to the cloudiness of both antra. Hemograms, urine examinations, and a chest X-ray were all found to be satisfactory. The individual tested negative for HIV and hepatitis B.



Figure 2: (a and b) CD45, (immunohistochemistry stain, ×4, ×40) (c and d) CD20 (immunohistochemistry stain, ×4, ×40)
Source: Singaraju et al., (2020)

[14]. Following a local anesthetic, an incisional biopsy was performed. Squamous mucosa with fundamental connective tissue constituted of dispersion, unvarying monotonous propagation of comparatively tiny, rotund cells with massive threateninglymark nuclei, and slight eosinophilic cytoplasm approximating lymphocytes in moveable fibro cellular myometrium and comedo necrosis provocative of lymphoproliferative disease were disclosed on microscopic images.

Immunohistochemistry (IHC) was used in this study. CD45 and CD20 were utilized as biomarkers, with CD45 positivity suggesting that the tumor cell is hematopoietic in source and CD20 undesirable suggesting that it is not B-lymphocytic in the source.

VI. TREATMENT

NHL can be treated in four ways.

International Journal Dental and Medical Sciences Research
Volume 4, Issue 5, Sep-Oct 2022 pp 137-143 www.ijdmsrjournal.com ISSN: 2582-6018

- Chemotherapy
- Immunotherapy
- Targeted therapy
- Radiation therapy

The Patient is frequently given a combination of these treatments. Surgery may be considered by the doctor and the patient on rare occasions.[16]. Several factors influence treatment options and suggestions, such as the NHL's kind and stage, side effects that may occur the patient's preferences as well as his overall health.

Therapies using medication

Medication-based treatments are castoff to destroy cancer cells. Medication can be injected straight into the blood to attain cancer cells entire body. Systemic treatment refers to the administration of medicine in this manner.[15]. Medication can also be provided locally, which means it is directly applied to cancer or stored in one location on the body. Medications are commonly administered either as an intravenous (IV) tube implanted into a vein with a pointer or as a pill or capsule eaten.

Each of the therapies is discussed below,

Chemotherapy

[2]. Chemotherapy is the use of medicines to destroy cancer cells by averting them from proliferating, separating, and creating new ones. It is the most common kind of treatment for NHL. A chemotherapy treatment, often recognized as a program, contains of a distinctnumber of cycles managed over a set length of period. A single drug may be administered to the patient at a time, or a mixture of medications may be specified at the equivalent time.Chemotherapy is chosen based on the phase and kind of NHL. CHOP is the most often used chemotherapy mixture for the first therapy of severe NHL. It consists of four medicines.

- Cyclophosphamide
- Doxorubicin
- Prednisone
- Vincristine

Chemotherapy side effects vary depending on the medicine and dosage utilized. [9]Fatigue, a brief drop in blood counts, an increased threat of infections, nausea and sickness, hair loss, a decreased appetite, a rash, and diarrhea are some of the symptoms. These adverse effects are normally manageable during treatment and disappear once it is completed.

Immunotherapy

Immunotherapy, also recognized as a biologic treatment, is a type of cancer handling that works by boosting the body's natural defenses. [7].Altered T cells and checkpoint inhibitors are among the lymphoma therapies in this group. It improves, targets, or restores immune system function using anti-lymphoma methods.

T-cell treatment with chimeric antigen receptors (CAR). Certain T cells are eliminated from a patient's blood after CAR T-cell treatment. The cells are then genetically engineered in the lab to produce certain proteins known as receptors. [19].The receptors permit T lymphocytes to identify and eliminate lymphoma cells that have the mark protein immunologically. The altered T cells are developed in high facts in the laboratory before being transfused back into the patient's body. They then find and extinguish cancer cells once they arrive.

- Yescarta (axicabtagene ciloleucel) is a CAR T-cell treatment licensed to treat individuals with DLBCL or recurring or persistent follicular lymphoma who have had at least two methods of handling previously.
- Tisagenlecleucel (Kymriah) is a CAR T-cell treatment licensed for the therapy of headstrong B-cell lymphoma, especially DLBCL, in patients who have failed two or more systemic therapies.
- Patients with recurrent or persistent mantle cell lymphoma can use brexucabtagene autoleucel (Tecartus).
- Breyanzi (lisocabtagene maraleucel) is a CAR T-cell treatment for individuals with recurring or refractory huge B-cell lymphoma following two or more appearances of standard treatment. It can be used to cure DLBCL that hasn't been classified yet, as well as high-grade B-cell lymphoma, recurrent mediastinal huge B-cell lymphoma, and follicular lymphoma.

Inhibitors of the immune system's checkpoints. This kind of immunotherapy inhibits or slows the development of cancer by blocking certain pathways. Many checkpoint inhibitors target the PD-1 mechanism. Pembrolizumab (Keytruda), one of these medicines, can be used to cure recurrent mediastinal huge B-cell lymphoma.

Targeted therapy

Targeted treatment is a type of handling that focuses on the genetic factor, proteins, or tissue microenvironment that promote cancer growth and sustainability. This method of treatment breaks cancer cells from mounting and spreading while limiting damage to healthy cells.

[1]. Monoclonal antibodies, kinase blockers, immunomodulatory medicines, and nuclear transfer inhibitors are some of the targeted

International Journal Dental and Medical Sciences Research
Volume 4, Issue 5, Sep-Oct 2022 pp 137-143 www.ijdmsrjournal.com ISSN: 2582-6018

therapeutics utilized to treat NHL. Monoclonal antibodies are the most common type of targeted treatment used to treat several forms of NHL. A monoclonal antibody detects and binds to anexact protein, but it does not disturb cells lacking that protein. Antibody-drug conjugates are pharmacologically active that are employed to convey an attached chemotherapeutic agent or toxin.

Monoclonal antibodies

Rituximab is a type of antibody that is used to treat cancer (Rituxan). Rituximab is a directed treatment that is used to indulgence a variety of B-cell NHL types. [11]. Itsmechanism by focusing on a molecule known as CD20, which is found on the superficial of both normal B cells as well as B-cell NHL. When the antibody binds to this element, the immune scheme of the patient is triggered, causing certain lymphoma cells to die or making lymphoma cells further vulnerable to chemotherapy.

VedotinBrentuximab (Adcetris). Brentuximab vedotin is a medication that combines an antibody and a drug. [6]. Antibody-drug conjugates bind to cancer cell targets and then proclamation a modest dose of chemotherapy or another poison into the tumor cells. The patient with specific types of outlying T-cell lymphoma, such as systemic anaplastic huge cell lymphoma, angioimmunoblastic T-cell lymphoma, as well as peripheral T-cell lymphoma, not otherwise stipulated, can receive Brentuximab vedotin in combination with chemotherapy, as long as the lymphoma expresses the CD30 proteintesirine-lpyl Loncastuximab (Zynlonta). The CD19 protein is targeted by the antibody-drug combo loncastuximab tesirine-lpyl. This is licensed for the handling of patients with B-cell lymphoma subtypes that haven't responded to two or more therapies.

Kinase inhibitor

Ibrutinib is a drug that inhibits Bruton's tyrosine kinase system.[18]. Mantle cell lymphoma, borderingregion lymphoma, as well as minor lymphocytic lymphoma, as well as prolonged lymphocytic leukemia, as well as Waldenstrom macroglobulinemia, are among the B-cell lymphomas for which it has been authorized. Diarrhea, muscle and bone pain, rash, nausea, bruises, weariness, and, fewer frequently, hemorrhage, staining, or abnormal heart rate are all possible adverse effects of ibrutinib.

Radiation therapy

A radiation treatment regimen, frequentlyrecognized as a program, is made up of a distinctnumber of actions administered over a set amount of time.

Based on the NHL subtype, radiation therapy is frequently specifiedafterward or in addition to chemotherapy. This is most commonly administered to persons with localized lymphoma, which affects only one or two neighboring locations, or to individuals who have a big lymph node, typically more than 7 to 10 cm across. It may also be administered to persons with progressive disease who have limited indications that can be treated with radiation treatment, such as a hurting bone lesion, in very low doses (just two treatments).

VII. FOLLOW UP AND OUTCOMES

Physical indications and side possessions, as well as psychological, interpersonal, and economic impacts, are all caused by cancer and its treatment. Palliative care, also known as supportive care, is the process of coping withall these side effects. It is a vital aspect of medical treatment, and this is included with medicines aimed at slowing, stopping, or eliminating cancer.[17]. Palliative care involves treating indications and assisting patients and their families with non-medical requirements while they are undergoing treatment. This form of treatment is available to everybody, irrespective of age, cancer type, or stage. And it was most effective when started soon after a cancer diagnosis. Individuals who obtain palliative care in addition to cancer therapy frequently have fewer symptoms, a higher life quality, and are more pleased with their therapy.

VIII. DISCUSSION

Malignant tiny round cell tumors are tumors made up of malignant round cells somewhat bigger than or twice the extent of red blood cells in air-dried smears. Small, circular, and generally undifferentiated cells describe this group of neoplasms. Ewing's sarcoma,peripheralneuroectodermal tumor, rhabdomyosarcoma, synovial sarcoma, NHL, retinoblastoma, neuroblastoma, are some of the most common cancers. [4].Minor cell osteogenic sarcoma, undistinguishablehepatoblastoma,granulocytic sarcoma, and intraabdominal desmoplastic tiny round cell tumors are some of the other diagnoses for little round cell tumors. Since the treatment options, reactions to medication, and prognostications differ greatly based on the diagnosis, accurate identification of these tumors is critical, and examinations are required.

Lymphoma is a broad word for a multifaceted collection of lymphoreticular system

tumors in this case study. These cancers start in the lymphatic tissues and proceed to extra nodular masses (NHL) or nontender abnormalities or commonalities in a lymph node region (HL), which can then migrate to other lymph node collections and affect the bone marrow. Lymphoma in the soft tissues of the mouth typically shows as an extra nodal, soft to firm asymptomatic lump, though the tumor can also be unpleasant. B-cell lymphoma, T-cell or NK cell lymphoma, and Hodgkin's lymphoma are the three principal kinds of lymphoid malignancies recognized by the WHO revision of the Modified European–American Lymphoma Category. [5]. NHL is one of the malignancies that can develop in the head and neck area, and it is the second most prevalent site for extramedullary NHLs after the gastrointestinal tract. Waldeyer's ring is the most prevalent site of origination in the head and neck, and it might be followed by cervical node invasion. Other probable organs impacted include the nose, paranasal sinus, orbits, and salivary glands, in order of decreasing incidence, with uncommon dissemination to nearby lymph nodes. [3]. NHL has long been known as a diverse group of diseases with different medical presentations, morphological appearances, and therapeutic responses. Immunological and molecular biology approaches have made significant advancements in the comprehension of lymphocyte differentiation in recent times, laying the groundwork for a greater empathetic of the cellular origin and pathophysiology of NHL. NHL refers to neoplastic cells that have been stopped at various phases in the normal differentiating arrangement or have developed a proliferating or anti-apoptotic aberration, the phenotypic of which is dependent on the developmental phase at which the lymphocyte is afflicted.

On the other hand, In contrast to Burkitt's lymphoma as well as mycosis fungoides, which are infrequentprocedures of the disease, Hodgkin's disease and NHLs are considered significant types. Hematologic malignancies such as HL and NHL are detected through a biopsy of an expanded lymph node or masses.[20]. Several patients with extranodal lymphoma have a local lump or pain as their first symptom. NHL has long been acknowledged as a diverse set of illnesses with differing medical presentations, morphological appearances, and therapeutic responses. Immunological and molecular biology approaches have made significant advancements in the comprehension of lymphocyte differentiation in recent years, laying the groundwork for a improvedconsiderate of the cellular origin and pathophysiology of NHL. Presently, different forms of NHL are supposed to signify neoplastic cells halted at numerous phases of usualdifference, even though crucial steps in malevolentalteration may happen in cells at an early point of distinction.

T-cell NHLs are a rare type of lymphoma that accounts for about 13 percent of all lymphomas. Lymphomas of the oral area have no distinct clinical symptoms, and they are dependent on the location of the enlargement, lymph node connection, and/or the existence of metastases. In the case of tonsillar NHL, the furthermostmutual early symptoms are a local lump, discomfort or pain, dysphagia, or a feeling of a foreign entity in the throat.[3] Extranodal disease is frequent in T-cell NHL, and biopsy specimens often include varying degrees of necrosis or apoptosis, rendering the distinction between a reactive process and lymphoma difficult. T-cell NHL has increased diagnostic ability, categorization, and prognostication thanks to immunophenotypic, cytogenetic, and genomic investigations. In 2016 WHO categorization of lymphoid neoplasms, there are 28 separates recognized as well as tentative mature T-cell or NK cell entities, grouped into two different groups: T-cell lymphoma of the peripheral blood and T-cell lymphoma of the skin.

The advantage of this case is, Other than epistaxis and blood after coughing, the patient showed no other symptoms. Extraoral examination indicated a minor asymmetry of the face. Females are more likely to have primary lymphomas. In this case, though, it was an elderly man.[10]. NHL is more prevalent in industrialized countries than in emergingstates. Few Middle Eastern countries demonstrate moderate-to-high intensity among developing nations. According to a study, the average age-adjusted incidence rate and proportion of yearly transformation in attuned rates of age for NHL by sex in urban areas increased statistically significantly during a two-decade period.

IX. PATIENT PERSPECTIVE

The Ann Arbor staging is used to address NHL that affects the head and neck. Radiotherapy only may be used to treat an indolent type; however, a widespread type will consist of a mixture of radiotherapy and chemotherapy. Medical enucleation is used to treat isolated lesions. For improved results, surgery is paired with radiotherapy as well as chemotherapy.

X. CONCLUSION

The outcome of the disease is determined by the phase of the disease, with a five-year endurance rate of 60 percentage points in the maxilla and mandible. Minorrotund cell tumors are

hard to differentiate using light microscopy, and there is presently no lone test that can accurately differentiate these tumors. As a result, pathologists should use a variety of different procedures, such as IHC, to corroborate the analysis. In many cases, IHC for particular protein indicators is employed to determine the diagnosis, and its overall correctness is likewise extremely high. As a result, IHC can aid in reducing the diagnostic evaluation of tiny round cell tumors, as well as determining treatment outcomes.

REFERENCES

[1]. Abdelwahed Hussein, M. (2018). Non-Hodgkin's lymphoma of the oral cavity and maxillofacial region: a pathologist viewpoint. ExpertReview Of Hematology, 11(9),737-748.
[2]. Alegbeleye, B., & Malikdoko, B. (2018). Primary Mammary (Non-Hodgkin) Lymphoma of Breast: a Rare Case Report. Open Science Journal, 3(1).
[3]. Armitage, J., Gascoyne, R., Lunning, M., & Cavalli, F. (2017). Non-Hodgkin lymphoma. The Lancet, 390(10091),298-310.
[4]. Celebi, N., Gonen, Z., Kilic, E., Etoz, O., & Alkan, A. (2011). Maxillary sinus floor augmentation in patients with maxillary sinus pseudocyst: case report. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, And Endodontology, 112(6),e97-e102.
[5]. Higgins, R., Blankenship, J., & Kinney, M. (2008). Application of Immunohistochemistry in the Diagnosis of Non-Hodgkin and Hodgkin Lymphoma. ArchivesOf Pathology & LaboratoryMedicine, 132(3),441-461.
[6]. Jaradat, J., Potluri, A., & Bilodeau, E. (2013). B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma: Report of a case in the oral cavity. Indian Journal Of DentalResearch, 24(3), 384.
[7]. Jayakrishnan, R., Thomas, G., Kumar, A., & Nair, R. (2008). Non-Hodgkin's lymphoma of the hard palate. Journal Of Oral And Maxillofacial Pathology, 12(2),85.
[8]. Kolte, S., Sekhon, S., Gupta, K., & Yadav, A. (2016). Atypical clinical presentations of lymphomas: Two case reports. Journal Of Mahatma Gandhi Institute Of Medical Sciences, 21(1), 50.
[9]. Manjunatha, B., Nagarajappa, D., Gowramma, R., & Tanveer, A. (2011). Extranodal non-Hodgkin′s lymphoma presenting as gingival mass. Journal Of Indian Society Of Periodontology, 15(4),418.
[10]. Matsuki, E., & Younes, A. (2016). Checkpoint Inhibitors and Other Immune Therapies for Hodgkinand Non-Hodgkin Lymphoma. Current Treatment Options In Oncology, 17(6).
[11]. Mochizuki, Y., Harada, H., Sakamoto, K., Kayamori, K., Nakamura, S., & Ikuta, M. et al. (2015). Malignant Lymphoma with Initial Symptoms in the Mandibular Region. Journal Of Cancer Therapy, 06(07),554-565.
[12]. Ninkovic, S., & Lambert, J. (2017). Non-Hodgkin lymphoma. Medicine, 45(5),297-304.
[13]. Nogai, H., Dörken, B., & Lenz, G. (2011). Pathogenesisof Non-Hodgkin's Lymphoma. Journal Of Clinical Oncology, 29(14), 1803-1811.
[14]. Rajwanshi, A., Srinivas, R., & Upasana, G. (2009). Malignant small round cell tumors. Journal Of Cytology, 26(1), 1.
[15]. Rao, I. (2010). Role of immunohistochemistry in lymphoma. Indian Journal Of Medical And Paediatric Oncology, 31(04), 145-147.
[16]. Rizvi, M., Evens, A., Tallman, M., Nelson, B., & Rosen, S. (2006). T-cell non-Hodgkin lymphoma. Blood, 107(4), 1255-1264.
[17]. Ryan, P., Patel, N., & Cullingham, P. (2015). Plasmablastic lymphoma of the maxillary sinus; a case report and review of the literature. Oral Surgery, 9(3), 188-192.
[18]. Scott, J., Selvan, S., Vinoth, P., Anand, C., Krishnaratnam, K., Rajendiran, S., & Sahni, L. (2012). Primary extra nodal non-Hodgkin′s lymphoma of the oral cavity in a young girl. National Journal Of Maxillofacial Surgery, 3(2), 187.
[19]. Selvi, S., Kar, R., Basu, D., Jacob, S., & Dubashi, B. (2015). Clinicopathological Analysis of B Cell Lymphomas, Unclassifiable; with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma in a Tertiary Care Hospital in Southern India. Indian Journal Of Hematology And Blood Transfusion, 32(2), 168-175.
[20]. Shaikh, A., Waghmare, S., Koshti-Khude, S., & Koshy, A. (2016). Unusual presentation of non-Hodgkin′s lymphoma: Case report and review of literature. Journal Of Oral And Maxillofacial Pathology, 20(3), 510.
[21]. Shankland, K., Armitage, J., & Hancock, B. (2012). Non-Hodgkin lymphoma. The Lancet, 380(9844), 848-857.

[22]. Singaraju, S., Patel, S., Sharma, A., & Singaraju, M. (2020). Non-Hodgkins lymphoma – A case report and review of literature. Journal Of Oral And Maxillofacial Pathology, 24(2), 322.
[23]. Swerdlow, S., Campo, E., Pileri, S., Harris, N., Stein, H., & Siebert, R. et al. (2016). The 2016 revision of the World Health Organization classificationof lymphoidneoplasms . Blood, 127(20), 2375-2390.
[24]. Zhang, Y., Dai, Y., Zheng, T., & Ma, S. (2011). Risk factors of non-Hodgkin's lymphoma. Expert Opinion On Medical Diagnostics, 5(6),539-550.